Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14359595 | 0.93 | HTR1A (0.60) | HTR1ASLC6A4MTNR1AHTR4 | |
| SCHEMBL14359435 | 0.91 | HTR1A (0.49) | HTR1ASLC6A4MTNR1A | |
| SCHEMBL15676381 | 0.87 | HTR1A (0.54) | HTR1ASLC6A4MTNR1AHTR7LTA4H | |
| SCHEMBL15675906 | 0.84 | HTR1A (0.58) | HTR1ASLC6A4MTNR1ALTA4H | |
| SCHEMBL14358795 | 0.82 | HTR1A (0.50) | HTR1ASLC6A4MTNR1A | |
| SCHEMBL8109895 | 0.80 | HTR1A (0.54) | HTR1ASLC6A4MTNR1AHTR7 | |
| SCHEMBL6365007 | 0.80 | HTR1A (0.54) | HTR1ASLC6A4MTNR1AHTR7 | |
| Hydrochloric Acid SCHEMBL9091527 | 0.79 | HTR1A (0.53) | HTR1ASLC6A4MTNR1AHTR7 | |
| SCHEMBL14358663 | 0.79 | HTR1A (0.54) | HTR1ASLC6A4HTR7 | |
| SCHEMBL14358972 | 0.78 | HTR1A (0.60) | HTR1ASLC6A4HTR7HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135310-A1 | SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | ADAMED SP. Z O.O. (PL) | 2014-05-15 | — | — | US | disclosed |
| EP-2726476-A2 | SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | Adamed sp. z o.o. (PL) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013001505-A2 | SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | ADAMED SP. Z O.O. (PL) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135310-A1 | SULPHONAMIDE DERIVATIVES OF ALICYCLIC AMINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | DDC, INA, SCN5A | HTR1A 646/4885SLC6A4 137/4885MTNR1A 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.